Evidence map›Paper›PMID 36767667›Full record

ArticleInternational journal of environmental research and public health2023

Randomized Controlled Trial Evaluating the Benefit of a Novel Clinical Decision Support System for the Management of COVID-19 Patients in Home Quarantine: A Study Protocol.

Irene Alcoceba-Herrero, María Begoña Coco-Martín, Luis Leal-Vega, Adrián Martín-Gutiérrez, Lidia Peña-de Diego, Carlos Dueñas-Gutiérrez, Flor de Castro-Rodríguez, Pablo Royuela-Ruiz, Juan F Arenillas-Lara

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Irene Alcoceba-HerreroGroup of Applied Clinical Neurosciences and Advanced Data Analysis, Department of Medicine, Dermatology and Toxicology, University of Valladolid, 47005 Valladolid, Spain.
María Begoña Coco-MartínGroup of Applied Clinical Neurosciences and Advanced Data Analysis, Department of Medicine, Dermatology and Toxicology, University of Valladolid, 47005 Valladolid, Spain.ORCID 0000-0001-9977-429X
Luis Leal-VegaGroup of Applied Clinical Neurosciences and Advanced Data Analysis, Department of Medicine, Dermatology and Toxicology, University of Valladolid, 47005 Valladolid, Spain.ORCID 0000-0002-7847-413X
Adrián Martín-GutiérrezGroup of Applied Clinical Neurosciences and Advanced Data Analysis, Department of Medicine, Dermatology and Toxicology, University of Valladolid, 47005 Valladolid, Spain.ORCID 0000-0002-9309-9796
Lidia Peña-de DiegoGroup of Applied Clinical Neurosciences and Advanced Data Analysis, Department of Medicine, Dermatology and Toxicology, University of Valladolid, 47005 Valladolid, Spain.
Carlos Dueñas-GutiérrezCOVID-19 Unit, Department of Internal Medicine, University Clinical Hospital of Valladolid, 47003 Valladolid, Spain.ORCID 0000-0002-8943-1231
Flor de Castro-RodríguezEmergency Medical Services (SEM) Direction, Sacyl, 47006 Valladolid, Spain.
Pablo Royuela-RuizTechnical Direction of Primary Care, Sacyl, 47007 Valladolid, Spain.
Juan F Arenillas-LaraGroup of Applied Clinical Neurosciences and Advanced Data Analysis, Department of Medicine, Dermatology and Toxicology, University of Valladolid, 47005 Valladolid, Spain.ORCID 0000-0001-7464-6101

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: We present the protocol of a randomized controlled trial designed to evaluate the benefit of a novel clinical decision support system for the management of patients with COVID-19. (2) Methods: The study will recruit up to 500 participants (250 cases and 250 controls). Both groups will receive the conventional telephone follow-up protocol by primary care and will also be provided with access to a mobile application, in which they will be able to report their symptoms three times a day. In addition, patients in the active group will receive a wearable smartwatch and a pulse oximeter at home for real-time monitoring. The measured data will be visualized by primary care and emergency health service professionals, allowing them to detect in real time the progression and complications of the disease in order to promote early therapeutic interventions based on their clinical judgement. (3) Results: Ethical approval for this study was obtained from the Drug Research Ethics Committee of the Valladolid East Health Area (CASVE-NM-21-516). The results obtained from this study will form part of the thesis of two PhD students and will be disseminated through publication in a peer-reviewed journal. (4) Conclusions: The implementation of this telemonitoring system can be extrapolated to patients with other similar diseases, such as chronic diseases, with a high prevalence and need for close monitoring.

Indexed as

COVID-19Decision Support Systems, ClinicalHumansPatientsQuarantineRandomized Controlled Trials as TopicSARS-CoV-2artificial intelligenceBig DataCOVID-19decision support systemmobile healthmonitoringtelemedicinewearable

Identifiers

PMID36767667
PMCPMC9915322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.